Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02774291 |
|
Recruitment Status : Unknown
Verified March 2020 by Ira Braunschweig, Albert Einstein College of Medicine.
Recruitment status was: Recruiting
First Posted : May 17, 2016
Last Update Posted : March 6, 2020
|
Sponsor:
Albert Einstein College of Medicine
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Ira Braunschweig, Albert Einstein College of Medicine
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | May 2020 |
| Estimated Study Completion Date : | May 2020 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
August 6, 2021 | September 1, 2021 |